First-line treatment (txt) with pemetrexed-cisplatin (PC), followed sequentially by gefitinib (G) or pemetrexed, in Asian, never-smoker (n/smkr) patients (pts) with advanced NSCLC: An open-label, randomized phase II trial.
2010 ◽
Vol 28
(15_suppl)
◽
pp. 7591-7591
◽
Keyword(s):
Phase Ii
◽